KYNB Kyntra BIO (KYNB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000921299
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
6
13F, latest reported quarter
What the filings say about KYNB
Insiders, 180 days
+$19.9K net bought
1 buyer
Kyntra BIO insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, KYNTRA BIO, INC. insiders bought a net $19.9K of stock across 1 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.3% of the 27,203 shares held after it.
- No other insider bought within 30 days.
- 6 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Wettig Thane bought about $19.9K of KYNB on May 14, 2026, the largest insider purchase at the company on our record; 6 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$19.9K over 180 days
more than 68% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
6 funds bought in last quarter
below 92% of Pharma & Biotech
Revenue
-78.3% year over year
below 87% of Pharma & Biotech
Margin
2848.6% net margin
the highest in Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.7% of the float short (float per yahoo 2026-10-27) · 3.5 days to cover · settled 2026-10-15
below 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch KYNB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-58.0%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns KYNB: institutional holders (13F)
13F holdings, latest reported quarter
400,000 sh
$3.0M
159,950 sh
$1.2M
84,330 sh
$636.7K
43,219 sh
$326.4K
39,746 sh
$300.1K
Congress trades in KYNB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
KYNB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
KYNB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$145.4K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$319.1K position · as of 2026-06-30
0.0%
VANGUARD CAPITAL OPPORTUNITY FUND
$20.5K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$13.7K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$26.5K position · as of 2026-06-30
0.0%
Knights of Columbus U.S. ALL CAP INDEX FUND
$147 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
1 active
8
Phase 3
1 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Second Peo
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$10.7M
$10.2M
$3.2M
+14%
n/a
2021
$10.4M
-$373.4K
$3.5M
-67%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $19.9K bought by insiders over 180 days, 6 funds added last quarter. Each figure is a federal filing, dated the day it went public.
KYNB financials
Revenue growth
-78.3%
XBRL, annual
Net margin
2848.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM KYNB
| FY Dec 2025 | $6.4M |
| FY Dec 2024 | $29.6M |
| FY Dec 2023 | $147.8M |
| FY Dec 2022 | $140.7M |
| FY Dec 2021 | $235.3M |
| Jun 2026 | -$1.5M |
| Mar 2026 | $3.7M |
| Dec 2025 | $1.3M |
| Sep 2025 | $1.1M |
| Jun 2025 | $1.3M |
| Mar 2025 | $2.7M |
| Dec 2024 | -$123.3M |
| Sep 2024 | $46.3M |
At each fiscal year end
Single quarter
Net margin, TTM
+3,968%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM KYNB
| FY Dec 2025 | +2,849% |
| FY Dec 2024 | -160.6% |
| FY Dec 2023 | -192.4% |
| FY Dec 2022 | -208.7% |
| FY Dec 2021 | -123.3% |
| Jun 2026 | n/a |
| Mar 2026 | -406.6% |
| Dec 2025 | -1,114% |
| Sep 2025 | +18,646% |
| Jun 2025 | -564.0% |
| Mar 2025 | +169.4% |
| Dec 2024 | n/a |
| Sep 2024 | -36.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$38.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM KYNB
| FY Dec 2025 | -$4.8M |
| FY Dec 2024 | -$138.3M |
| FY Dec 2023 | -$317.5M |
| FY Dec 2022 | -$149.7M |
| FY Dec 2021 | -$87.4M |
| Jun 2026 | -$4.0M |
| Mar 2026 | -$13.9M |
| Dec 2025 | -$18.3M |
| Sep 2025 | -$1.9M |
| Jun 2025 | $12.7M |
| Mar 2025 | $2.7M |
| Dec 2024 | -$30.6M |
| Sep 2024 | -$8.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity KYNB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.51x
TTM operating cash flow over long-term debt only, 2025-08-29 (10 months older than the period end)
Cash flow to debt KYNB
| FY Dec 2025 | -0.06x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.51x |
| Mar 2026 | -0.29x |
| Dec 2025 | -0.06x |
| Sep 2025 | -0.23x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity KYNB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -312.9% |
| FY Dec 2021 | -91.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+131.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets KYNB
| FY Dec 2025 | +109.8% |
| FY Dec 2024 | -14.9% |
| FY Dec 2023 | -55.0% |
| FY Dec 2022 | -42.4% |
| FY Dec 2021 | -36.2% |
| Jun 2026 | +131.3% |
| Mar 2026 | +119.1% |
| Dec 2025 | +109.8% |
| Sep 2025 | +107.4% |
| Jun 2025 | -0.9% |
| Mar 2025 | -3.8% |
| Dec 2024 | -14.9% |
| Sep 2024 | -33.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital KYNB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-115.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed KYNB
| FY Dec 2025 | -53.5% |
| FY Dec 2024 | -104.8% |
| FY Dec 2023 | -119.0% |
| FY Dec 2022 | -68.0% |
| FY Dec 2021 | -47.6% |
| Jun 2026 | -115.4% |
| Mar 2026 | -51.7% |
| Dec 2025 | -53.5% |
| Sep 2025 | -45.2% |
| Jun 2025 | -98.1% |
| Mar 2025 | -89.0% |
| Dec 2024 | -104.8% |
| Sep 2024 | -146.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.10x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing KYNB
| FY Dec 2025 | 0.19x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.19x |
| Sep 2025 | 0.23x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$42.6M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2025-08-29 (10 months older than the period end), minus cash 2026-06-30
Enterprise value KYNB
| FY Dec 2025 | $62.6M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $54.9M |
| Mar 2026 | $65.4M |
| Dec 2025 | $62.6M |
| Sep 2025 | $6.6M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-208.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield KYNB
| FY Dec 2025 | -13.5% |
| FY Dec 2024 | -10.4% |
| FY Dec 2023 | -14.6% |
| FY Dec 2022 | -0.4% |
| FY Dec 2021 | -0.3% |
| Jun 2026 | -124.5% |
| Mar 2026 | -78.0% |
| Dec 2025 | -13.5% |
| Sep 2025 | -34.5% |
| Jun 2025 | -4.4% |
| Mar 2025 | -9.7% |
| Dec 2024 | -10.4% |
| Sep 2024 | -12.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing KYNB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $147.8M | $140.7M |
| Operating income | -$45.9M | -$150.4M | -$322.7M | -$301.0M |
| Net income | $183.5M | -$47.6M | -$284.2M | -$293.7M |
| EPS (diluted) | 45.37 | -11.89 | -2.92 | -3.14 |
| Operating cash flow | -$4.8M | -$138.0M | -$315.0M | -$145.9M |
| Cash | $47.9M | $50.5M | $81.6M | $155.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
KYNB Stock Sonar score 6/7 axes
Find similar shapesCompareKYNB ranks highest on risk and compliance (72nd percentile) and insider conviction (61st), and lowest on institutional and government (8th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
KYNB filings, in plain words
Are Kyntra BIO insiders buying or selling KYNB?
In the 180 days to 2026-10-28, Kyntra BIO insiders were net buyers, a net $19.9K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Kyntra BIO insiders were net buyers of KYNB, a net $19.9K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
